About T.Rx Capital
T.Rx Capital is a venture capital firm founded in 2023. It is primarily based out of Boston, United States. As of Nov 2025, T.Rx Capital is an active investor, having invested in 3 companies, with 1 new investment in the last 12 months. It primarily invests in Seed round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and High Tech. Most recently it participated in the $***** Series D round of Synchron A lot of funds co-invest with T.Rx Capital, with names like Double Point Ventures sharing a substantial percentage of its portfolio. T.Rx Capital has team of 16 people including 3 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Seed, Series B & 1 more
Deals in last 12 months
T.Rx Capital's List of All Investments
T.Rx Capital has a portfolio of 3 companies. Their most notable investmentis in PursueCareTheir portfolio spans across and United States. They have invested in Life Sciences, HealthTech, High Tech and 1 other sectors, across stages such as Seed, Series B and 1 more. Here is the list of all investments by T.Rx Capital:
1. Synchron
Developer of implantable bioelectronics for the treatment of neurological conditions. The company offers a motor neuroprosthesis the Stentrode which helps paralyzed patients regain the ability to communicate. Also, provides endovascular neuromodulation minimally invasive device that stimulates brain or nerve activity for the treatment of Parkinson’s disease, epilepsy, depression, and others.
Key facts about Synchron
- Founded Year: 2016
- Location: Brooklyn (United States)
- Stage: Series D
- Total Funding till date: $345M
- Employee Count: 126 as on Mar 31, 2026
- Investors: AXIAL Partners, Gates Frontier and 32 Others
- Latest Funding Round: Series D, Nov 06, 2025, $*****
- Highlight: Editors' Pick
2. ImmuneBridge
Developer of allogeneic cellular medicines to treat cancer. The company is developing the next generation of allogeneic cellular medicines, starting with NK cell-based immunotherapies, to make curative cancer therapies accessible to everyone.
Key facts about ImmuneBridge
- Founded Year: 2018
- Location: San Francisco (United States)
- Stage: Seed
- Total Funding till date: $19.7M
- Employee Count: 16 as on Apr 30, 2026
- Investors: LongGame, Gaingels and 8 Others
- Latest Funding Round: Seed, Mar 24, 2025, $*****
- Highlight: Editors' Pick
3. PursueCare
The user can select a professional and book an appointment for teleconsultation. The professional provides personalized substance abuse treatment and addiction therapy. The prescriptions can be sent via mail-order and the company also offers insurance plans.
Key facts about PursueCare
- Founded Year: 2018
- Location: Middletown (United States)
- Stage: Series B
- Total Funding till date: $31M
- Employee Count: 58 as on Apr 30, 2026
- Investors: Starboard Capital Partners, T.Rx Capital and 5 Others
- Latest Funding Round: Series B, Dec 13, 2023, $*****
- Highlight: Editors' Pick
T.Rx Capital's Year-on-Year Investment Trends
T.Rx Capital has invested in 3 companies over the last 3 years, with an average of 1 new investment annually in the last 3 years. In 2025, it made 2 investments. Its most recent first time investment was in Synchron.T.Rx Capital's Investments by Stage
T.Rx Capital has made 1 investment in Seed stage with an average round size of $7.7M, 1 investment in Series B stage with an average round size of $20M and 1 investment in Series D stage with an average round size of $200M.Stage of entry | No. of Investments |
|---|---|
Seed | 1 |
Series B | 1 |
Series D | 1 |
Note: We have considered here, only first round of investments
T.Rx Capital's Investments by Sector
T.Rx Capital has a diverse portfolio, with companies operating in the Life Sciences, Consumer, HealthTech and High Tech. Notably, it has invested in 3 Enterprise (B2B) companies, 3 Tech companies, 1 Consumer (B2C) company and at least 1 company focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 2 |
Consumer | 1 |
HealthTech | 1 |
High Tech | 1 |
Note: We have considered here, only first round of investments
T.Rx Capital's Investments by Geography
T.Rx Capital has made most investments in United States (3).T.Rx Capital's recent investments
T.Rx Capital has not made any investment in 2026 so far.Here are the most recent investments by T.Rx Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Nov 06, 2025 | United States | Series D | 6757 | [+10] | |
Mar 24, 2025 | United States | Seed | 6532 | [+6] | |
Dec 13, 2023 | United States | Series B | 9658 |
Team profile of T.Rx Capital
T.Rx Capital has a team of 16 members including 3 Partners, 1 Venture Partner and 1 Principal located in United States. T.Rx Capital's team does not sit on the board of any company as of now.Here is a list of top team members in T.Rx Capital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Boston | - | ||
Partner | Miami Beach | - | ||
Partner | - | - | ||
Venture Partner | - | - | ||
Principal | - | - |
Co-investors of T.Rx Capital
Over the past 3 years, 43 investors have co-invested in T.Rx Capital's portfolio companies. This includes funds and angels.
- Invested before T.Rx Capital: Future Fund, Khosla Ventures and 30 others have invested in rounds before T.Rx Capital. There is 1 company where Future Fund has invested before T.Rx Capital and 1 company where Khosla Ventures has invested before T.Rx Capital.
- Top Co-investors of T.Rx Capital: 11 investors entered a company along with T.Rx Capital. These include investors like Double Point Ventures (1 company).
Recent News related to T.Rx Capital
•
Synchron Raises $200 Million Series D to Advance Brain-Computer Interface TechnologyBusiness Wire•Nov 06, 2025•Synchron, National Reconstruction Fund, Double Point Ventures, T.Rx Capital and 9 others
•
T.Rx Capital closes $77M inaugural fundEndpoints•Sep 18, 2025•T.Rx Capital, Third Rock Ventures, Arch Venture Partners, Polaris Partners and 1 other
•
